MPTP effects on dopamine neurons.
Kopin
I J
IJ
National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland 20892.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001679:Biogenic Amines / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D015198:Designer Drugs; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011725:Pyridines / Q000494:pharmacology / Q000633:toxicity*; D013045:Species Specificity
D001679:Biogenic Amines; D015198:Designer Drugs; D011725:Pyridines; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D004298:Dopamine